{
}
Sage Therapeutics and Biogen have decided to abandon efforts to gain approval for Zurzuvae in the broader major depressive disorder market, focusing instead on postpartum depression after the FDA limited its use. The companies are prioritizing resources due to the significant investment required for further studies, leading to a 40% workforce reduction at Sage. Despite setbacks, executives remain optimistic about Zurzuvae's performance in postpartum depression, noting encouraging prescription trends and insurance coverage.
Sage Therapeutics' experimental drug dalzanemdor (SAGE-718) has failed in a mid-stage trial for Alzheimer’s, showing no significant cognitive improvement over placebo. Following this setback, the company will not pursue further development for Alzheimer’s and faces low expectations for upcoming Huntington’s disease trials. Sage's stock has dropped significantly this year, reflecting ongoing challenges after previous drug failures and a major workforce reduction.
Barry Greene
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
biogen and sage shift focus to zurzuvae for postpartum depression
16:38 30.10.2024
sage therapeutic drug fails in alzheimer's trial amid ongoing challenges
14:21 08.10.2024
Trending
Subcategory
Countries:
Companies:
Currencies:
People: